Patent · US Active

Optimized DNA sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins

US8530637B2 · kind B2 · utility

16Cited by

1References

23Claims

0Family size

Assignee

CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS · DE

Inventors

Winfried Wels · Emmendingen, DE
Benjamin Daelken · Frankfurt am Main, DE
Sylvia E. Schwarz · Frankfurt am Main, DE

Key dates

Filing date	Jan 6, 2011
Grant date	Sep 10, 2013
Priority date	—
Expiry date	Jan 6, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/55
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.